Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Down 6.27%
As of Tuesday, September 29, Pulse Biosciences, Inc.’s PLSE share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. PLSE
$51.20
-2.61
-4.84%
October 12, 2026 3:15:31 PM
EST
Volume: 275,201
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Commentary & Analysis
Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Up 6.18%
As of Wednesday, September 23, Pulse Biosciences, Inc.’s PLSE share price has surged by 6.18%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Up 6.68%
As of Thursday, September 17, Pulse Biosciences, Inc.’s PLSE share price has surged by 6.68%, which has investors questioning if this is right time to sell.Michael Rose
Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Down 5.53%
As of Wednesday, September 16, Pulse Biosciences, Inc.’s PLSE share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Down 10.85%
As of Wednesday, September 16, Pulse Biosciences, Inc.’s PLSE share price has dipped by 10.85%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,837.9 | $385.5 | 64% |
|
| Shares Out (Mil) | 69.2 | 40.8 | 55% |
|
| Institutional Ownership | 17.9% | 83.0% | 9% |
|
| Float (Mil) | 20.6 | 35.5 | 29% |
|
| Beta | 1.58 | 0.85 | 84% |
|
| Avg Daily Volume (000s) | 441 | 321 | 56% |
|
| Price Change (52-week) |
169.9% | 64.6% | 98% |
|
| Growth | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (7.8%) | (5.5%) | 31% |
|
| EPS (5yr) | 12.8% | 10.2% | 52 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.8%) | (15.5%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.288) | ($1.108) | ($1.170) | |
| Month Ago EPS | ($0.295) | ($1.105) | ($1.155) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.285) | ($1.070) | ($1.090) | |
| Year/Year Chg | (19.1%) | 2.6% | (7.7%) | |
| Financials | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $155 | 2% |
|
| Net Income (TTM) (Mil) | ($80) | ($9) | 13% |
|
| EPS (TTM) | ($1.176) | ($0.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($2) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $1 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $27 | 25% |
|
| Enterprise Value (Q1) (Mil) | $2,930 | $418 | 54% |
|
| Valuation | PLSE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 38.16 | 2.69 | 98% |
|
| P/E | na | 24.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 0.3% | 58.5% | 5% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (67.9%) | (12.2%) | 9% |
|
| ROE | (78.5%) | (10.5%) | 11% |
|
| Liabilities to Assets | 13.9% | 47.2% | 9% |
|
| F-Score | 3 | 4 | 18% |
|
Pulse Biosciences, Inc. did not pass any screens on 10/9/2026.
